Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Public ClinicalTrials.gov record NCT05477186. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Prevention of COVID-19 caused by SARS-CoV-2.
Study identification
- NCT ID
- NCT05477186
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 185 participants
Conditions and interventions
Conditions
Interventions
- CV0501 (3 μg) Biological
- CV0501 (6 μg) Biological
- CV0501 (12 μg) Biological
- CV0501 (25 μg) Biological
- CV0501 (50 μg) Biological
- CV0501 (100 μg) Biological
- CV0501 (200 μg) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 12, 2022 (Actual)
- Primary completion
- Aug 18, 2023 (Actual)
- Completion
- Aug 18, 2023 (Actual)
- Last update posted
- Feb 21, 2025
2022 – 2023
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Sacramento | California | 95864 | — |
| GSK Investigational Site | Hollywood | Florida | 33024 | — |
| GSK Investigational Site | Melbourne | Florida | 32934 | — |
| GSK Investigational Site | Savannah | Georgia | 31406 | — |
| GSK Investigational Site | Peoria | Illinois | 61614-4896 | — |
| GSK Investigational Site | Metairie | Louisiana | 70006-5322 | — |
| GSK Investigational Site | Rockville | Maryland | 20854 | — |
| GSK Investigational Site | Omaha | Nebraska | 68134 | — |
| GSK Investigational Site | Binghamton | New York | 13760 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45212 | — |
| GSK Investigational Site | Norfolk | Virginia | 68701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05477186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 21, 2025 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05477186 live on ClinicalTrials.gov.